[|Since psoriasis is a polygenic disease, it cannot be the outcome of a
single cell anomaly – again, here I disagree strongly.|auteur195]
[|I strongly support the statement "psoriasis
is the outcome of a skin cell anomaly". Indeed, we cannot consider psoriasis a
defect in one cell type. Although T-cells have received a lot of attention, it
is intriguing that anti-TNFa
treatments are more effective as compared to T-cell specific approaches. It is
the broad interaction of TNF-a which
proves to be essential for a substantial therapeutic effect, whilst T-cell
targeted treatments have a more modest efficacy.|auteur197]
It has been clearly demonstrated for over 30 years now, particularly by Gerald Krueger, that grafting lesional or non lesional psoriatic skin onto a nude mouse ends in maintaining a psoriatic phenotype in the form of persistent epidermal hyperproliferation, when comparing these grafts with normal skin grafts. This epidermal hyperproliferation is only produced if the dermis is also grafted, indicating that dermal cells are necessary for the expression of a psoriatic phenotype. More recently, it has been shown that activated T lymphocytes from a psoriasis plaque, when injected into a psoriatic skin grafted onto a nude mouse, led to the appearance of a clinical and histological psoriasis plaque. By contrast, injecting these same cells into normal skin grafted onto the nude mouse does not have this effect. The inflammatory cells, therefore, only cause psoriasis to appear if they encounter abnormal skin cells.
SPIN Presentation
Recent news
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis.
J Dermatolog Treat.
2019 Nov , 30, (7):668-673.
: Biologics are modern immunomodulatory drugs, whose use in the treatment of psoriasis has led to remarkable results in psoriatic patients. The administration of these agents in special population groups, such as patients with chronic infections and renal impairment, as well as perioperative, pregnant or lactating patients, has not been thoroughly addressed, mostly because these patients are excluded from clinical studies. This report is an updated systematic overview of the use of (...)
see on pubmed
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
Vasconcelos V et al.
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat.
2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)
see on pubmed
on Atopic Dermatitis
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat.
2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
